By Adam Bonislawski

SAN DIEGO – The familiar questions of reproducibility and throughput loomed large at the Association for Mass Spectrometry's fourth annual Applications to the Clinical Lab meeting, held here this week.

But while such technical hurdles still limit the utility of mass spec-based proteomics, several vendor announcements and research presentations indicated that the field is moving ever closer to fulfilling its clinical promise.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.